Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours (Q45183894)
Jump to navigation
Jump to search
scientific article published on 16 November 2004
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours |
scientific article published on 16 November 2004 |
Statements
1 reference
Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours (English)
1 reference
Jos H Beijnen
1 reference
Jan H M Schellens
1 reference
Nadja E Schoemaker
1 reference
I E L M Kuppens
1 reference
Wim W Ten Bokkel Huinink
1 reference
Patricia Lefebvre
1 reference
Sylvie Assadourian
1 reference
Ger-Jan Sanderink
1 reference
16 November 2004
1 reference
1 reference
55
1 reference
3
1 reference
263-270
1 reference
Identifiers
1 reference
1 reference